Answers are grounded in this paper and cite their sources.
Head and neck cancers (HNCs) are a heterogenous group of malignancies with diverse molecular drivers and etiologies complicating the identification of reliable biomarkers and therapeutic targets. MicroRNA-142 (miR-142) dysregulation has been implicated in various cancers with its role being highly context-dependent. This review summarizes current research on miR-142 in HNC, exploring how its dysregulation influences proliferation, apoptosis, and metastatic processes. While findings for proliferation and apoptosis are inconsistent, showing both context dependent tumor-suppressive and oncogenic phenotypes, evidence supports miR-142 as a suppressor of invasive and metastatic phenotypes. Lastly, we examine the promising potential of miR-142 as a prognostic and diagnostic biomarker, particularly in relation to HPV status. Overall, miR-142 has a complex role in HNC but represents a promising biomarker and therapeutic target, with additional study needed before clinical translation.
No takes yet. Share an insight, caveat, or question.
Sandle et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: